Composition containing angiotensin II receptor antagonist, statin and folic acid as well as applications thereof

An angiotensin and receptor antagonist technology, which is applied in the field of compositions and applications containing angiotensin II receptor antagonist, statin and folic acid, can solve the problem of the combination of ARB, statin lipid-lowering drugs and folic acid. and other problems, to achieve the effect of reducing ventricular diastolic insufficiency, reducing the effect, and enhancing stiffness

Active Publication Date: 2009-12-02
SHENZHEN AUSA PHARM CO LTD +2
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] There is no report on the combination of ARB, statin lipid-lowering drugs and folic acid in clinical and existing research. Based on the above considerations, we have conducted research on the combined application of ARB, statin lipid-lowering drugs and folic acid, and obtained impressive results. satisfactory results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing angiotensin II receptor antagonist, statin and folic acid as well as applications thereof
  • Composition containing angiotensin II receptor antagonist, statin and folic acid as well as applications thereof
  • Composition containing angiotensin II receptor antagonist, statin and folic acid as well as applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1: Protective effect of losartan + atorvastatin + folic acid on target organ in hypertensive rats with dyslipidemia

[0043] 1. Preparation of compound model animals

[0044] For SD rats, the experiment was started after 5 days of adaptive feeding. Two kidneys and one clip operation were performed to prepare 2K1C hypertensive model animals. After feeding for 6 weeks, the blood pressure of the rats was measured (measured three times to get the average value). If the blood pressure > 140mmHg, the model was considered successful, and the model group began to gavage fat emulsion (cholesterol 10g, propylene glycol 20ml, bile salt 2g, Tween-80 20ml, 1g of propylthiouracil, 20ml of peanut oil, 20g of sucrose, after dissolving, add distilled water to 200ml) 10ml / kg and free drinking water (containing 1% methionine), after 4 weeks of intragastric administration of fat emulsion (retest after 2 weeks of infusion of fat emulsion) Blood pressure at one time) The rats were ...

Embodiment 2

[0089] Example 2: Protective effect of telmisartan + simvastatin + folic acid on target organ damage in stroke-susceptible spontaneously hypertensive (SHR-SP) rats with dyslipidemia

[0090] A total of 80 male SHR-SP rats about 8 weeks old were divided into model group, telmisartan+simvastatin (0.25+1mg / kg) group, telmisartan+simvastatin+folic acid group according to the blood pressure value. (0.25+1+0.08mg / kg) group and a WKY control group, 20 rats in each group. Oral administration, once a day, weighed once a week, adjust the dose according to body weight, for 8 consecutive weeks.

[0091] Observation indicators:

[0092] (1) Observation of general state: daily observation of animal diet, survival and behavior, and comparison between groups.

[0093] (2) Blood pressure: Blood pressure was measured before administration, 4 weeks and 8 weeks after administration, and the effect of medication on blood pressure of hypertensive rats with hyperlipidemia was observed.

[0094] (...

Embodiment 3

[0110] Example 3: Target Organ Protection of Irbesartan + Pitavastatin + Folic Acid on Rats with Hypertension and Dyslipidemia

[0111] The compound model animals of 2K1C hypertension with dyslipidemia were prepared by the same method as in Example 1, and the hypertensive and dyslipidemia animals were selected for group administration, and the administration time was 16 weeks.

[0112] Observation indicators

[0113] (1) Blood pressure: Blood pressure was measured before administration, 8 weeks and 16 weeks after administration, and the effect of medication on blood pressure in 2K1C hypertensive rats with hyperlipidemia was observed.

[0114] (2) Blood sugar and blood lipids: After the administration, blood was collected to measure plasma cholesterol (measured with a kit) and blood sugar levels by biochemical methods.

[0115] (3) Endothelial cells and antioxidant function: blood was collected as above, and serum NO, ET-1, SOD, MDA levels were determined by biochemical method...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist, statin lipid-lowering drugs and folic acid compound. The pharmaceutical composition contains medicinal dose of angiotensin II receptor antagonist, medicinal dose of statin lipid-lowering drugs, medicinal dose of folic acid composite and a carrier acceptable in pharmaceutics. The invention also relates to an application of the pharmaceutical composition in preparing medicines for preventing and treating or retarding high blood pressure accompanied by dyslipidemia and the application thereof in preparing medicines for treating target organ damage caused by the high blood pressure accompanied by dyslipidemia; in addition, the invention further relates to the application of the pharmaceutical composition in preparing medicines for lowering risk of cardiovascular and cerebrovascular events caused by high blood pressure accompanied by dyslipidemia. The invention belongs to the pharmaceutical field. With the implementation of the invention, the pharmaceutical composition with special usage, provided to the patients, can improve compliance of the patients, bring convenience to the patients to take medicines and reduce medical expenses, thus enjoying good market prospect.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist (ARB), statin lipid-lowering drugs and folic acid, and the preparation of the pharmaceutical composition for preventing, treating or delaying hypertension with dyslipidemia The use in medicine and the use in medicine of target organ damage caused by hypertension accompanied by dyslipidemia, and the present invention also relates to the preparation of the pharmaceutical composition for reducing the risk of cardiovascular and cerebrovascular events caused by hypertension accompanied by dyslipidemia the use of. belongs to the field of pharmacy. Background technique [0002] Major risk factors for cardiovascular disease include: hypertension, dyslipidemia, smoking, age (≥55 years), male sex, history of stroke, peripheral artery disease, diabetes, proteinuria, left ventricular hypertrophy, family history of coronary heart disease, and high homocysteine Amin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61P9/12A61P3/06A61P9/10
Inventor 陈明侠陈光亮徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap